nih-gov/heal.nih.gov/funding/awarded/export?research_program=151&_format=csv

"Project #","Project Title","Research Focus Area","Research Program","Administering IC(s)",Institution(s),Investigator(s),Location(s),"Year Awarded",Summary
,"Development of Vaccines for the Treatment of Opioid Use Disorder","Novel Therapeutic Options for Opioid Use Disorder and Overdose","Development of Novel Immunotherapeutics for Opioid Addiction",NIAID,"Boston Children's Hospital","Ofer Levy","Boston, MA",2020,"High rates of relapse and overdose deaths pose significant challenges to the treatment of Opioid Use Disorder (OUD).  Anti-opioid immunotherapies (i.e., vaccines and monoclonal antibodies) have great potential to reduce long-term opioid use and overdose, with minimal risk of side effects, when used in conjunction with pharmacological treatments and/or behavioral therapies. The ability of an anti-opioid vaccine to induce antibodies that render an opioid less effective, or less rewarding, and protect from accidental overdose could provide an important therapeutic option for patients undergoing treatment for OUD.  The goal of this collaborative study is to design, develop, and evaluate vaccines for use in the treatment of opioid use disorder"
,"Adjuvanted Opioid Vaccine for Treating Fentanyl Use Disorder to Reduce Poisoning and Fatal Overdose","Novel Therapeutic Options for Opioid Use Disorder and Overdose","Development of Novel Immunotherapeutics for Opioid Addiction",NIAID,"University of Montana","Jay Evans","Missoula, Montana",2020,"High rates of relapse and overdose deaths pose significant challenges to the treatment of Opioid Use Disorder (OUD).  Anti-opioid immunotherapies (i.e., vaccines and monoclonal antibodies) have great potential to reduce long-term opioid use and overdose, with minimal risk of side effects, when used in conjunction with pharmacological treatments and/or behavioral therapies. The ability of an anti-opioid vaccine to induce antibodies that render an opioid less effective, or less rewarding, and protect from accidental overdose could provide an important therapeutic option for patients undergoing treatment for OUD.  The goal of this collaborative study is to design, develop, and evaluate vaccines for use in the treatment of opioid use disorder"
	`"Project #","Project Title","Research Focus Area","Research Program","Administering IC(s)",Institution(s),Investigator(s),Location(s),"Year Awarded",Summary`
	,"Development of Vaccines for the Treatment of Opioid Use Disorder","Novel Therapeutic Options for Opioid Use Disorder and Overdose","Development of Novel Immunotherapeutics for Opioid Addiction",NIAID,"Boston Children's Hospital","Ofer Levy","Boston, MA",2020,"High rates of relapse and overdose deaths pose significant challenges to the treatment of Opioid Use Disorder (OUD). Anti-opioid immunotherapies (i.e., vaccines and monoclonal antibodies) have great potential to reduce long-term opioid use and overdose, with minimal risk of side effects, when used in conjunction with pharmacological treatments and/or behavioral therapies. The ability of an anti-opioid vaccine to induce antibodies that render an opioid less effective, or less rewarding, and protect from accidental overdose could provide an important therapeutic option for patients undergoing treatment for OUD. The goal of this collaborative study is to design, develop, and evaluate vaccines for use in the treatment of opioid use disorder"
	,"Adjuvanted Opioid Vaccine for Treating Fentanyl Use Disorder to Reduce Poisoning and Fatal Overdose","Novel Therapeutic Options for Opioid Use Disorder and Overdose","Development of Novel Immunotherapeutics for Opioid Addiction",NIAID,"University of Montana","Jay Evans","Missoula, Montana",2020,"High rates of relapse and overdose deaths pose significant challenges to the treatment of Opioid Use Disorder (OUD). Anti-opioid immunotherapies (i.e., vaccines and monoclonal antibodies) have great potential to reduce long-term opioid use and overdose, with minimal risk of side effects, when used in conjunction with pharmacological treatments and/or behavioral therapies. The ability of an anti-opioid vaccine to induce antibodies that render an opioid less effective, or less rewarding, and protect from accidental overdose could provide an important therapeutic option for patients undergoing treatment for OUD. The goal of this collaborative study is to design, develop, and evaluate vaccines for use in the treatment of opioid use disorder"